SAN DIEGO & SHANGHAI-Sirius Therapeutics today announced that preliminary data from its Phase 1 clinical trial of SRSD107, a next-generation siRNA therapeutic in clinical development for the prevention and treatment of thromboembolic diseases, will be presented at the American Society of Hematology (ASH) 66th Annual Meeting & Exposition. The meeting will be held December 7-10, 2024 at the San Diego Convention Center and online.
“The data presented at ASH 2024 demonstrate a favorable safety and efficacy profile of SRSD107, pointing to its potential as a transformative drug with semi-annual or even annual dosing for patients requiring a chronic anticoagulant”
The data presented at ASH 2024 demonstrate a favorable safety and efficacy profile of SRSD107, pointing to its potential as a transformative drug with semi-annual or even annual dosing for patients requiring a chronic anticoagulant,” said Dr. Patrick Yue, CMO of Sirius Therapeutics.
This announcement is officially valid in the original source language. Translations are provided as a reading aid only and should be compared with the source-language text, which alone has legal validity.
Contacts
Official website:
www.siriusrna.com
